• Listen: Every angle on the FDA's polarizing approval of Biogen's Alzheimer's drug

    13 days ago - By STAT

    Was the FDA right to approve Aduhelm? What's a fair price for a debatable drug? And what does this have to do with '80s HIV activism?
    We cover all that and more this week on “The Readout LOUD,” STAT's biotech podcast. We're devoting this entire episode to the FDA's polarizing decision to approve Aduhelm, a controversial Biogen treatment for Alzheimer's disease. First, we'll break down what happened and why it's such a big deal, and then we'll talk about the broader implications for science, medicine, and the drug industry as a whole. Finally, we'll zoom out explore how the FDA got to this...
    Read more ...

     

  • STAT+: What's next for the new Alzheimer's drug? Lots of thorny issues ahead

    13 days ago - By STAT

    Despite all the excitement surrounding the FDA's approval on Mondayof a controversial treatment for Alzheimer's disease, the drug won't be flowing into a lot of patients' arms anytime soon.
    Aduhelm, made by Cambridge-based Biogen, poses an array of thorny issues that have yet to be untangled, including how to provide the monthly hour-long infusions and whether insurers will pay for the drug despite the $56,000 annual price tag. And some consumers may face hefty out-of-pocket charges, which could make them think twice about taking a drug with known risks and uncertain benefits. Continue to...
    Read more ...